Lucid Diagnostics INC 8-K filings

Lucid Diagnostics has rescheduled its 2024 annual meeting of stockholders from June 20, 2024, to July 23, 2024, to modify the proposals to be voted upon.

Lucid Diagnostics announced a 10% increase in EsoGuard test volume for Q1 2024, alongside a strengthened balance sheet following a $29.8 million Series B Preferred Stock Offering.

Lucid Diagnostics closed a $11.6 million Series B-1 preferred stock offering and appointed healthcare veteran Dennis Matheis to its board of directors.

Lucid Diagnostics reports the peer-reviewed publication of positive data from a National Cancer Institute-sponsored study, highlighting the effectiveness of its EsoGuard test in detecting early esophageal precancer.

Lucid Diagnostics has raised $18.16 million through the sale and exchange of preferred stock, strengthening its financial position.

Lucid Diagnostics issued 3,331,771 shares of its common stock to its parent company, PAVmed, to cover $4,675,256 in fees and reimbursements accrued from October 1, 2022, through December 31, 2022.